title: Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
abstract: Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial cancer. Although it represents only 10% of all endometrial cancer cases, USC accounts for up to 40% of all endometrial cancer-related recurrences and subsequent deaths. With such a dismal prognosis, there is an expanding role for novel targeted approaches in the treatment of USC. Recent whole-exome sequencing studies have demonstrated gain of function of the HER2/NEU gene, as well as driver mutations in the PIK3CA/AKT/mTOR and cyclin E/FBXW7 oncogenic pathways in a large number of USCs. The results emphasize the relevance of these novel therapeutic targets for biologic therapy of USC, which will be reviewed in this article.
authors.affiliation: Section of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
authors.forename: Gulden
authors.initials: G
authors.lastname: Menderes
authors.affiliation: Department of Obstetrics and Gynecology, Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT 06610, USA.
authors.forename: Mitchell
authors.initials: M
authors.lastname: Clark
authors.affiliation: Section of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
authors.forename: Alessandro D
authors.initials: AD
authors.lastname: Santin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D058534:Class I Phosphatidylinositol 3-Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D019927:Cyclin E / Q000037:antagonists & inhibitors / Q000235:genetics; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016889:Endometrial Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D034261:Epothilones / Q000627:therapeutic use; D059472:Exome / Q000235:genetics; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015513:Oncogene Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D054648:Protein Phosphatase 2 / Q000235:genetics; D016499:Radioimmunotherapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D017422:Sequence Analysis, DNA; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics; D050257:Tubulin Modulators / Q000627:therapeutic use; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D014594:Uterine Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D058534:Class I Phosphatidylinositol 3-Kinases; D019927:Cyclin E; D034261:Epothilones; D015513:Oncogene Proteins; D047428:Protein Kinase Inhibitors; D054648:Protein Phosphatase 2; D018719:Erb-b2 Receptor Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases; D050257:Tubulin Modulators; D016159:Tumor Suppressor Protein p53; D042461:Vascular Endothelial Growth Factor A; C475820:CCNE1 protein, human; C517191:PPP2R1A protein, human; C495901:TP53 protein, human; C467484:VEGFA protein, human; C546842:MTOR protein, human; C484760:PIK3CA protein, human; C508053:ERBB2 protein, human